NLRC5 potentiates anti-tumor CD8+ T cells responses by activating interferon-β in endometrial cancer

Autor: Jing Zhang, Bao Guo, Jia-Hua Chen, Xiao-Jing Liu, Jun-Hui Zhang, Hai-Qing Zhu, Wen-Yan Wang, Zhen-Hai Tang, Bing Wei, Yun-Xia Cao, Lei Zhan
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Translational Oncology, Vol 36, Iss , Pp 101742- (2023)
Druh dokumentu: article
ISSN: 1936-5233
DOI: 10.1016/j.tranon.2023.101742
Popis: Objectives: NLR family CARD domain containing 5 (NLRC5) could promote major histocompatibility complex class I (MHC-I)-dependent CD8+ T cell-mediated anticancer immunity. In this study, the immunosurveillance role and underlying mechanisms of NLRC5 in endometrial cancer (EC) were characterized. Methods: CD8+ T cells were separated from healthy women's peripheral blood by using magnetic beads. The effect of NLRC5 and interferon-β (IFN-β) on immunosurveillance of EC were examined through a mouse tumor model and a CD8+ T cell-EC cell coculture system after NLRC5 overexpression and IFN-β overexpression or depletion. The effect of NLRC5 on IFN-β expression was examined with gain- and loss-of-function experiments. Results: NLRC5 overexpression in the EC cell and CD8+ T cell coculture system inhibited EC cell proliferation and migration and promoted EC cell apoptosis and CD8+ T cell proliferation. In vivo, NLRC5 overexpression increased the proportion of CD8+ T cells and inhibited EC progression. Furthermore, IFN-β overexpression in the EC cell and CD8+ T cell coculture system activated CD8+ T cell proliferation; however, genetic depletion of IFN-β exerted the opposite effects. In addition, NLRC5 could negatively regulate IFN-β expression in EC cells. Mechanistically, NLRC5 potentiated the antitumor responses of CD8+ T cells to EC by activating IFN-β. Conclusions: Taken together, our findings demonstrated that NLRC5 potentiates anti-tumor CD8+ T cells responses by activating interferon-β in EC, suggesting that genetically escalated NLRC5 and IFN-β may act as potential candidates for the clinical translation of adjuvant immunotherapies to patients with EC.
Databáze: Directory of Open Access Journals